Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prasugrel - Daiichi Sankyo/Eli Lilly

Drug Profile

Prasugrel - Daiichi Sankyo/Eli Lilly

Alternative Names: CS-747; CS-747S; Effient; Efient; LY 640315; Prasugrel-hydrochloride; R 99224

Latest Information Update: 14 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company; Ube Industries
  • Developer Daiichi Sankyo Company; Eli Lilly; Kurume University; Ube Industries
  • Class Antiplatelets; Antithrombotics; Cardiovascular therapies; Cyclopropanes; Fluorobenzenes; Small molecules; Thienopyridines
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes
  • Phase III Sickle cell anaemia; Stroke
  • Phase II Ischaemic heart disorders

Most Recent Events

  • 25 Oct 2018 Daiichi Sankyo Company completes the phase II CONVERT 2 trial in Ischaemic heart disorders in Japan (PO) (UMIN000027089)
  • 01 Oct 2018 Daiichi Sankyo Company initiates the phase III PRASTRO-III trial for Stroke in Japan (PO) (JapicCTI-184141)
  • 25 Aug 2018 Efficacy data from the phase IV TROPICAL-ACS trial in Acute coronary syndromes presented at the Annual Congress of the European Society of Cardiology (ESC-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top